AbbVie vs Johnson & Johnson

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...

REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy

REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.

• 60% of Dose Level 3 participants (n=6/10) achieved >2-step DRSS improvement at 3 years post-treatment.
• No vision-threatening events or additional treatment for diabetic retinopathy observed in these participants.
• No intraocular inflammation (IOI) observed with short-course prophylactic topical steroids through three years.

A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma

Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation. First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA.

8-K Financial Filing Analysis for Johnson & Johnson

Johnson & Johnson filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on July 15, 2026, announcing its financial results for the fiscal second quarter ended June 28, 2026. The filing furnishes the official quarterly press release alongside unaudited comparative supplementary sales data and condensed consolidated statements of earnings for both the second quarter and the first six months of the fiscal year.

• Johnson & Johnson released its sales and earnings report for the second quarter ended June 28, 2026, via Item 2.02.
• The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
• The report was formally signed on July 15, 2026, by Controller and Principal Accounting Officer Robert J. Decker, Jr.